Adult‐onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity

Christopher Koh, Sasan Sakiani, Pallavi Surana, Xiongce Zhao, Jason Eccleston, David E. Kleiner, David Herion, T. Jake Liang, Jay H. Hoofnagle, Milica Chernick, Theo Heller – 19 April 2017 – Cystic fibrosis (CF) liver disease (CFLD), a leading cause of death in CF, is mostly described in pediatric populations. Adult‐onset CFLD lacks sufficient characterization and diagnostic tools. A cohort of CF patients without CFLD during childhood were followed for up to 38 years with serologic testing, imaging, and noninvasive fibrosis markers.

Hepatic artery reconstruction in living donor liver transplantation using surgical loupes: Achieving low rate of hepatic arterial thrombosis in 741 consecutive recipients—tips and tricks to overcome the poor hepatic arterial flow

Ping‐Chun Li, Ashok Thorat, Long‐Bin Jeng, Horng‐Ren Yang, Ming‐Li Li, Chun‐Chieh Yeh, Te‐Hung Chen, Shih‐Chao Hsu, Kin‐Shing Poon – 19 April 2017 – The reconstruction of the hepatic artery (HA) is the most complex step in living donor liver transplantation (LDLT) because of the smaller diameter of the artery and the increased risk of HA‐related complications. Because of the smaller diameter of the HA, many centers use a microsurgical technique with interrupted sutures for arterial anastomosis.

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction

Paula Cox‐North, Kelsey L. Hawkins, Sean T. Rossiter, Marie N. Hawley, Renuka Bhattacharya, Charles S. Landis – 18 April 2017 – Sofosbuvir (SOF) is a nonstructural 5B polymerase inhibitor with activity in all hepatitis C virus (HCV) genotypes and is the backbone of many anti‐HCV drug regimens. SOF is converted into inactive metabolites that undergo renal excretion.

Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

Jerry R. Colca, William G. McDonald, Kyle S. McCommis, Brian N. Finck – 18 April 2017 – Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193‐197)

Same policy, different impact: Center‐level effects of share 35 liver allocation

Douglas R. Murken, Allison W. Peng, David D. Aufhauser, Peter L. Abt, David S. Goldberg, Matthew H. Levine – 13 April 2017 – Early studies of national data suggest that the Share 35 allocation policy increased liver transplants without compromising posttransplant outcomes. Changes in center‐specific volumes and practice patterns in response to the national policy change are not well characterized. Understanding center‐level responses to Share 35 is crucial for optimizing the policy and constructing effective future policy revisions.

Subscribe to